Examination of the active secondary structure of the peptide 101.10, an allosteric modulator of the interleukin-1 receptor, by positional scanning using β-amino γ-lactams

Journal of Peptide Science

Volumn 17, Issue 4, 2011, Pages 288-296

  Boutard, Nicolas ^a   Turcotte, Stéphane ^a   Beauregard, Kim ^a,b   Quiniou, Christiane ^b   Chemtob, Sylvain ^b   Lubell, William D ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

101.10; CD; Conformational analysis; Freidinger lactams; Interleukin 1 receptor; Lactam scanning; Peptide mimic; Solid phase peptide synthesis; amino lactam; turn

Indexed keywords

ASPARTIC ACID; BETA AMINO ACID; DEXTRO ASPARTIC ACID; GAMMA LACTAM DERIVATIVE; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR 101.10; INTERLEUKIN 1BETA; RESIN; UNCLASSIFIED DRUG;

ALLOSTERISM; AMINO ACID SEQUENCE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN SYNTHESIS; THYMOCYTE;

EID: 79952480235     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1337     Document Type: Article

References (34)

1. Arend WR. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002; 13: 323-340. DOI:10.1016/S1359-6101(02)00020-5.
2. Mee JB, Cork MJ, di Giovine FS, Duff GW, Groves RW. Interleukin-1: A key inflammatory mediator in psoriasis? Cytokine 2006; 33: 72-78. DOI:10.1016/j.cyto.2005.12.001.
3. Billiau A, Vandekerckhove F. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur. J. Clin. Invest. 1991; 21: 559-573. DOI:10. 1111/j.1365-2362.1991.tb01410.x.
4. Luheshi GN. Cytokines and fever: mechanisms and sites of action. Ann. N. Y. Acad. Sci. 1998; 856: 83-89. DOI:10. 1111/j.1749-6632.1998.tb08316.x.
5. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv. Ther. 2006; 23: 208-217. DOI:10.1007/BF02850127.
6. Arend WP. Interleukin-1 receptor antagonist. Adv. Immunol. 1993; 54: 167-227. DOI:10.1016/S0065-2776(08)60535-0.
7. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G, Study G. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis-a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003; 48: 927-934. DOI:10.1002/art.10870.
8. Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, Boule M, Sarazin P, Stea D, Lacombe D, Tremblay P, Gervais F. Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. J. Biol. Chem. 2003; 278: 34874-34881. DOI:10.1074/jbc.M212694200.
9. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M. A peptide derived from a beta(2)-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J. Biol. Chem. 1996; 271: 16384-16392. DOI:10. 1074/jbc.271.27.16384.
10. McDonnell JM, Beavil AJ, Mackay GA, Jameson BA, Korngold R, Gould HJ, Sutton BJ. Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor. Nat. Struct. Biol. 1996; 3: 419-426. DOI:10.1038/nsb0596-419.
11. Peri KG, Quiniou C, Hou X, Abran D, Varma DR, Lubell WD, Chemtob S. THG113: a novel selective FP antagonist that delays preterm labor. Semin. Perinatol. 2002; 26: 389-397. DOI:10.1053/sper.2002.37307.
12. Zhang TT, Cui B, Dai DZ, Tang XY. Pharmacological efficacy of CPU 86017 on hypoxic pulmonary hypertension in rats-mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway. J. Cardiovasc. Pharmacol. 2005; 46: 727-734.
13. Smeets RL, Joosten LAB, Arntz OJ, Bennink MB, Takahashi N, Carlsen H, Martin MU, van den Berg WB, van de Loo FAJ. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum. 2005; 52: 2202-2211. DOI:10.1002/art.21108.
14. Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003; 31: 3784-3788. DOI:10.1093/nar/gkg563.
15. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 1982; 157: 105-132. DOI:10. 1016/0022-2836(82)90515-0.
16. Rost B, Fariselli P, Casadio R. Topology prediction for helical transmembrane proteins at 86% accuracy. Protein Sci. 1996; 5: 1704-1718. DOI:10.1002/pro.5560050824.
17. Casadio R, Frigimelica E, Bossu P, Neumann D, Martin MU, Tagliabue A, Boraschi D. Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1 beta/IL-1R(I) complex. FEBS Lett. 2001; 499: 65-68. DOI:10.1016/S0014-5793(01)02515-7.
18. Vigers GPA, Anderson LJ, Caffes P, Brandhuber BJ. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1 beta. Nature 1997; 386: 190-194. DOI:10.1038/386190a0.
19. Quiniou C, Sapieha P, Lahaie I, Hou X, Brault S, Beauchamp M, Leduc M, Rihakova L, Joyal JS, Nadeau S, Heveker N, Lubell W, Sennlaub F, Gobeil F, Miller G, Pshezhetsky AV, Chemtob S. Development of a novel noncompetitive antagonist of IL-1 receptor. J. Immunol. 2008; 180: 6977-6987.
20. Chemtob S, Quiniou C, Lubell WD, Beauchamp M, Hansford KA. Interleukin-1 receptor antagonists, compositions, and methods of treatment, patent n° US2006094663 (A1), 2010.
21. Jamieson AG, Boutard N, Beauregard K, Bodas MS, Ong H, Quiniou C, Chemtob S, Lubell WD. Positional scanning for peptide secondary structure by systematic solid-phase synthesis of amino lactam peptides. J. Am. Chem. Soc. 2009; 131: 7917-7927. DOI:10. 1021/ja9010628.
22. Ronga L, Jamieson AG, Beauregard K, Quiniou C, Chemtob S, Lubell WD. Insertion of multiple α-amino γ-lactam (Agl) residues into a peptide sequence by solid-phase synthesis on Synphase lanterns. J. Pept. Sci. 2010; 94: 183-191. DOI:10.1002/bip.21288.
23. Freidinger RM, Veber DF, Schwenk Perlow D, Brooks JR, Saperstein R. Bioactive conformation of luteinizing hormone-releasing hormone: evidence from a conformationally constrained analog. Science 1980; 210: 656-658. DOI:10.1126/science.7001627.
24. Ede NJ, Rae ID, Hearn MTW. Synthesis and conformation of constrained peptides with hypoglycemic activity derived from human growth-hormone. Int. J. Pept. Protein Res. 1994; 44: 568-581. DOI:10.1111/j.1399-3011.1994.tb01146.x.
25. Dolbeare K, Pontoriero GF, Gupta SK, Mishra RK, Johnson RL. Iso-lactam and reduced amide analogues of the peptidomimetic dopamine receptor modulator 3(R)-(2(S)pyrrolidinylcarbonyl)amino-2-oxo-1-pyrrolidineacetamide. Bioorg. Med. Chem. 2003; 11: 4103-4112. DOI:10.1016/s0968-0896(03)00396-1.
26. 2. J. Med. Chem. 1988; 31: 1430-1436. DOI:10. 1021/jm00402a031.
27. Boutard N, Jamieson AG, Ong H, Lubell WD. Structure-activity analysis of the growth hormone secretagogue GHRP-6 by α- and β-Amino γ-lactam positional scanning. Chem. Biol. Drug Des. 2010; 75: 40-50. DOI:10.1111/j.1747-0285.2009.00913.x.
28. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970; 34: 595-598.
29. Haugland RP, Yue ST, Millard PJ, Roth BL. U.S. Patent n° 5, 436, 134. 1995.
30. Fields GB, Noble RL. Solid-phase peptide-synthesis utilizing 9-fluorenylmethoxycarbonyl amino-acids. Int. J. Pept. Protein Res. 1990; 35: 161-214. DOI:10.1111/j.1399-3011.1990.tb00939.x.
31. Lubell WD, Blankenship JW, Fridkin G, Kaul K. Science of Synthesis, Volume 21: Three Carbon-Heteroatom Bonds: Amide and Derivatives; Peptides; Lactams. Weinreb SM (ed.). Thieme: Stuttgart, 2005; 713-810. DOI:10.1055/tcsos-021(2006.1)-00693.
32. Boutard N, Jamieson AG, Lubell WD. Breaking Away: Proceedings of the 21st American Peptide Symposium. Lebl M (ed.). American Peptide Society: San Diego, 2009; 78-79.
33. Toniolo C. Conformationally restricted peptides through short-range cyclizations. Int. J. Pept. Protein Res. 1990; 35: 287-300. DOI:10.1111/j.1399-3011.1990.tb00052.x.
34. Holzwarth G, Doty P. Ultraviolet circular dichroism of polypeptides. J. Am. Chem. Soc. 1965; 87: 218-228. DOI:10.1021/ja01080a015.